使用SU6656、PP2和达沙替尼靶向头颈部肿瘤细胞中的Src家族激酶
研究在三种Src家族激酶(SFK)活性水平不同的头颈部鳞状细胞癌(HNSCC)细胞系中,用增殖与集落形成实验、Western blot和功能性激酶组学分析SFK抑制剂SU6656、PP2和达沙替尼的作用。结果示三种抑制剂在微摩尔范围内均阻断增殖;就细胞杀伤而言达沙替尼最有效、SU6656中等、PP2作用微弱。信号传导受影响方式各异,PP2对SFK信号无影响,达沙替尼可能具有非SFK特异性作用,仅SU6656显示明确的SFK特异性信号效应。结论示SFK抑制在HNSCC中具有潜在获益,但也凸显不同药物非特异性带来的挑战。
要点
- 在三种SFK活性水平不同的HNSCC细胞系中,SU6656、PP2和达沙替尼均在微摩尔范围阻断增殖。
- 就细胞杀伤而言,达沙替尼最有效,SU6656作用中等,PP2作用微弱。
- 仅SU6656显示明确的SFK特异性信号效应;PP2对SFK信号无影响,达沙替尼可能具有非SFK特异性作用。
核心结论
- 结果证明SFK抑制在HNSCC中具有潜在获益,但也凸显不同药物非特异性带来的挑战。
研究设计与样本
- 研究分析SU6656、PP2和达沙替尼三种SFK抑制剂对三种SFK活性水平不同的HNSCC细胞系的影响。
- 采用增殖与集落形成实验、Western blot和功能性激酶组学进行分析。
主要发现
- 三种抑制剂在微摩尔范围内均阻断增殖。
- 就细胞杀伤而言,达沙替尼最有效,SU6656作用中等,PP2作用微弱。
- 细胞信号受影响方式不同,PP2对SFK信号无影响,达沙替尼可能具有非SFK特异性作用。
- 仅SU6656显示明确的SFK特异性信号效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have recently shown a frequent upregulation of Src-family kinases (SFK) in head and neck squamous cell carcinoma (HNSCC). Here we tested, if SFK targeting is effective especially in HNSCC cells with upregulated SFK signaling. METHODS: The impact of SFK inhibitors SU6656, PP2 and dasatinib on three HNSCC cell lines with different SFK activity levels was analyzed using proliferation and colony formation assays, Western blot and functional kinomics. RESULTS: Proliferation was blocked by all inhibitors in a micro-molar range. With respect to cell kill, dasatinib was most effective, while SU6656 showed moderate and PP2 minor effects. Cellular signaling was affected differently, with PP2 having no effect on SFK signaling while dasatinib probably has non-SFK specific effects. Only SU6656 showed clear SFK specific effects on signaling. CONCLUSION: The results demonstrate potential benefit of SFK inhibition in HNSCC but they also highlight challenges due to non-specificities of the different drugs.
引用
- Vu AT, Akingunsade L, Hoffer K, et al. Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib. Head Neck. 2022. PMID: 36285353. doi:10.1002/hed.27216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。